Study backs Shield's heart disease prediction test
This article was originally published in Clinica
Executive Summary
Shield Diagnostics received a boost last week, after preliminary results from a multi-centre UK trial backed its Activated Factor XII (AFT) heart disease prediction test. Shares in the Scottish company rose 25 pence to 645 pence.